Kleo pharmaceuticals receives ind authorization to proceed from fda for its multiple myeloma therapeutic

Kleo pharmaceuticals receives ind authorization to proceed from fda for its multiple myeloma therapeutic.kleo pharmaceuticals - trial is expected to begin enrollment in first half of 2020, topline data are expected in second half of 2021.
BHVN Ratings Summary
BHVN Quant Ranking